Stock comparison
Caris Life Sciences, Inc. is 2.0x more valuable than VERACYTE, INC. by market capitalization ($6.75 B vs $3.36 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
CAI is larger
Caris Life Sciences, Inc. is 2.0x more valuable than VERACYTE, INC. by market capitalization ($6.75 B vs $3.36 B).
Market value leader
CAI
Caris Life Sciences, Inc. is 2.0x more valuable than VERACYTE, INC. by market capitalization ($6.75 B vs $3.36 B).
Revenue leader
CAI
VCYT: $517.14M vs CAI: $812.03M.
Profit leader
VCYT
VCYT: $66.40M vs CAI: -$68.09M.
Margin leader
VCYT
VCYT: 12.8% vs CAI: -8.4% net margin.
| Metric | VCYT | CAI |
|---|---|---|
| Market cap | $3.36 B | $6.75 B |
| US-listed rank | #1726 | #1187 |
| Revenue (latest FY) | $517.14M | $812.03M |
| Net income (latest FY) | $66.40M | -$68.09M |
| Net margin | 12.8% | -8.4% |
| P/E (trailing FY) | 50.7x | - |
| SEC filings | 1,122 | 102 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Caris Life Sciences, Inc. is 2.0x more valuable than VERACYTE, INC. by market capitalization ($6.75 B vs $3.36 B).
In their latest fiscal years, VERACYTE, INC. reported $517.14M in revenue while Caris Life Sciences, Inc. reported $812.03M.
Full pages: VERACYTE, INC. and Caris Life Sciences, Inc., or browse the full rankings.